Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11705940 | 0.81 | ALDH1A1 (0.53) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E | |
| SCHEMBL14124751 | 0.79 | KMT2A (0.56) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E | |
| SCHEMBL7336041 | 0.78 | NR4A2 (0.55) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E | |
| SCHEMBL629199 | 0.77 | CDC25B (0.54) | ALDH1A1KMT2AHSD17B10KDM4EGLA | |
| SCHEMBL20644867 | 0.77 | CYP1A2 (0.49) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E | |
| Glutarate SCHEMBL28854333 | 0.76 | PARP1 (0.57) | ALDH1A1KMT2AHSD17B10KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL5750101 | 0.76 | CDC25B (0.53) | ALDH1A1KMT2AHSD17B10KDM4EGLA | |
| Menbutone SCHEMBL30277792 | 0.76 | CYP2C9 (0.69) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E | |
| Menbutone SCHEMBL1641812 | 0.76 | CYP2C9 (0.69) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E | |
| SCHEMBL818033 | 0.75 | ALDH1A1 (0.63) | CYP1A2ALDH1A1KMT2AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321560-A1 | Method for Obtaining Novel Derivatives of Naphthalene for the In Vivo Diagnosis of Alzheimer's Disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2012-12-20 | — | — | US | claimed |
| US-10155053-B2 | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of Alzheimer's disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2018-12-18 | — | — | US | disclosed |
| EP-2860169-B1 | Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of Alzheimer's disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2018-08-29 | — | — | EP | disclosed |
| US-9764047-B2 | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2017-09-19 | — | — | US | disclosed |
| US-20150217005-A1 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTHALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER'S DISEASE | SABLON CARRAZANA MARQUIZA (CU) | 2015-08-06 | — | — | US | disclosed |
| EP-2860169-A2 | Method for obtaining novel derivatives of naphtalene for the in vivo diagnosis of Alzheimer's disease | Centro De Neurociencias De Cuba (CU) | 2015-04-15 | — | — | EP | disclosed |
| US-20120321560-A1 | Method for Obtaining Novel Derivatives of Naphthalene for the In Vivo Diagnosis of Alzheimer's Disease | CENTRO DE NEUROCIENCIAS DE CUBA (CU) | 2012-12-20 | — | — | US | disclosed |
| EP-2436666-A2 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER 'S DISEASE | Centro De Neurociencias De Cuba (CU) | 2012-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321560-A1 | Method for Obtaining Novel Derivatives of Naphthalene for the In Vivo Diagnosis of Alzheimer's Disease | SLC43A1, SLCO2B1, SLCO2A1 | CYP1A2 1183/4885ALDH1A1 1269/4885KMT2A 2327/4885 |
| US-20150217005-A1 | METHOD FOR OBTAINING NOVEL DERIVATIVES OF NAPHTHALENE FOR THE IN VIVO DIAGNOSIS OF ALZHEIMER'S DISEASE | SLC43A1, SLCO2B1, FABP7 | CYP1A2 1126/4885ALDH1A1 1358/4885KMT2A 2355/4885 |
| US-10155053-B2 | Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of Alzheimer's disease | SLC43A1, SLCO2B1, FABP7 | CYP1A2 1126/4885ALDH1A1 1358/4885KMT2A 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.